PI3K-Akt Signaling in Parkinson's Disease

Overview

The PI3K-Akt signaling pathway represents one of the most critical cell survival pathways in the nervous system, and its dysfunction plays a central role in Parkinson’s disease pathogenesis. This pathway regulates neuronal survival, mitochondrial function, autophagy, and protein homeostasis—all processes compromised in PD. Understanding PI3K-Akt signaling provides insights into disease mechanisms and therapeutic targets.

PI3K-Akt Pathway Overview

Class I PI3K Activation

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that phosphorylate phosphatidylinositol (4,5)-bisphosphate (PIP2) to generate phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Class IA PI3Ks consist of a p85 regulatory subunit and a p110 catalytic subunit. In neurons, PI3K activation occurs through:

1. Receptor tyrosine kinase activation: Growth factors bind to RTKs (TrkA, TrkB, IGF-1R)

2. IRS-1/2 recruitment: Insulin receptor substrate proteins dock at phosphotyrosine motifs

3. PI3K membrane recruitment: p85 SH2 domains bind phosphorylated IRS

4. PIP3 generation: p110 catalytic subunit phosphorylates PIP2 to PIP3

Akt Activation

Akt (PKB) is a serine/threonine kinase with three isoforms (Akt1, Akt2, Akt3) expressed in the brain. Akt activation requires:

1. PH domain binding: Akt PH domain binds PIP3 at the plasma membrane

2. PDK1 phosphorylation: Phosphoinositide-dependent kinase-1 phosphorylates Akt at Thr308

3. mTORC2 phosphorylation: mTOR complex 2 phosphorylates Akt at Ser473

4. Full activation: Fully activated Akt translocates to various cellular compartments

Downstream Targets

mTOR Complex 1

Akt directly activates mTORC1 through multiple mechanisms:

• TSC2 phosphorylation: Akt phosphorylates tuberin (TSC2), relieving mTORC1 inhibition

• Rheb activation: Active Rheb-GTP directly activates mTORC1

• Translation regulation: mTORC1 promotes protein synthesis via S6K and 4E-BP1

In PD, mTORC1 dysregulation affects:

• Autophagy inhibition: mTORC1 suppresses autophagy, leading to protein aggregate accumulation

• Synaptic plasticity: Altered translation affects synaptic function

• Cell growth: Aberrant mTORC1 signaling disrupts neuronal homeostasis

GSK-3β Inhibition

Akt phosphorylates GSK-3β at Ser9, inhibiting its kinase activity. GSK-3β is a key tau kinase and its dysregulation contributes to:

• Tau hyperphosphorylation: Active GSK-3β phosphorylates tau at multiple sites

• α-Synuclein aggregation: GSK-3β may promote α-synuclein phosphorylation at Ser129

• Mitochondrial dysfunction: GSK-3β affects mitochondrial quality control

Bad and Apoptosis Regulation

Akt phosphorylates the pro-apoptotic protein Bad at Ser136, sequestering it in the cytoplasm and preventing apoptosis. This provides a critical survival signal for dopaminergic neurons, which are particularly vulnerable to apoptotic insults.

PD-Related Alterations

Reduced Akt Signaling in PD Brains

Post-mortem studies of PD substantia nigra demonstrate:

• Decreased Akt phosphorylation at both Thr308 and Ser473

• Reduced PI3K activity

• Increased PTEN activity (negative regulator)

• Correlation between Akt reduction and disease severity

Genetic Links

Several PD-linked genes affect PI3K-Akt signaling:

Mitochondrial PI3K-Akt Dysfunction

PI3K-Akt signaling critically regulates mitochondrial quality control:

• PGC-1α activation: Akt promotes mitochondrial biogenesis via PGC-1α

• Mitophagy: Akt regulates autophagy of damaged mitochondria

• Mitochondrial dynamics: Akt affects fission/fusion balance

• Energy metabolism: Akt influences glycolysis and oxidative phosphorylation

Therapeutic Implications

Growth Factor Approaches

Neurotrophic factors that activate PI3K-Akt:

• GDNF: Glial cell line-derived neurotrophic factor activates Ret receptor → PI3K-Akt

• BDNF: Brain-derived neurotrophic factor via TrkB

• IGF-1: Insulin-like growth factor-1

Small Molecule Activators

• ** Akt activators**: Direct Akt activators in development

• mTOR inhibitors: Rapamycin and analogs to restore autophagy

• GSK-3β inhibitors: To reduce tau pathology

Gene Therapy Targets

• AAV-GDNF: Clinical trials for PD

• AAV-BDNF: Neuroprotective approaches

• PI3K isoform-specific modulators: Targeting neuronal PI3K-C2α

Mermaid Diagram: PI3K-Akt Pathway in PD

flowchart TD
    A["Growth Factors<br/>GDNF, BDNF, IGF-1"]  -->  B["RTK / Trk Receptors"]
    B  -->  C["IRS-1/2"]
    C  -->  D["PI3K p85/p110"]
    D  -->  E["PIP3 Production"]
    E  -->  F["Akt Recruitment"]
    F  -->  G["PDK1"]
    F  -->  H["mTORC2"]
    G  -->  I["Akt Thr308 Phos"]
    H  -->  J["Akt Ser473 Phos"]
    I  -->  K["Fully Active Akt"]
    J  -->  K

    K  -->  L["mTORC1 Activation"]
    K  -->  M["GSK-3beta Inhibition"]
    K  -->  N["Bad Phosphorylation"]
    K  -->  O["PGC-1alpha Activation"]

    L  -->  P["Protein Synthesis"]
    L  -->  Q["Autophagy Inhibition"]
    M  -->  R["Tau Phosphorylation down"]
    M  -->  S["alpha-Syn Phosphorylation down"]
    N  -->  T["Apoptosis Block"]
    O  -->  U["Mitochondrial Biogenesis"]

    V["PD Pathology"]  -->  W["alpha-Syn Aggregation"]
    V  -->  X["Mitochondrial Dysfunction"]
    V  -->  Y["Autophagy Impairment"]

    W  -->  Z["PI3K-Akt Inhibition"]
    X  -->  Z
    Y  -->  Z
    Z -.-> |Reduced| D

    style K fill:#0e2e10
    style T fill:#3b1114
    style Z fill:#3b1114

Clinical Evidence in Parkinson’s Disease

Post-Mortem Studies

Multiple studies have documented PI3K-Akt pathway dysregulation in PD brain tissue:

• Substantia nigra pars compacta: Reduced Akt phosphorylation at both Thr308 and Ser473 sites compared to age-matched controls ^{1Saluja I, Gupta V. Parkinson's disease and Akt signaling. *Clin Schizophr Relat Psychoses*. 2010;4(2):119-1272010 · DOI 10.3371/CSRP.4.2.4Open reference}

• Frontal cortex: Altered PI3K subunit expression, particularly reduced p85α

• Temporal correlation: Degree of Akt inhibition correlates with disease duration and severity

Biomarker Studies

Peripheral blood studies have identified:

• Lymphocyte Akt activity: Reduced in PD patients compared to healthy controls

• Serum IGF-1: Decreased levels correlate with motor symptom severity

• CSF biomarkers: Phospho-Akt/total Akt ratio reduced in PD CSF

Neuroimaging Correlations

PET studies using Akt pathway markers suggest:

• Reduced Akt signaling in the substantia nigra correlates with dopaminergic neuron loss

• Akt pathway activity predicts response to dopaminergic therapy

Therapeutic Development

Growth Factor Therapy

GDNF (Glial Cell Line-Derived Neurotrophic Factor)

GDNF activates the PI3K-Akt pathway through Ret receptor tyrosine kinase, providing potent neuroprotection for dopaminergic neurons:

BDNF (Brain-Derived Neurotrophic Factor)

BDNF activates TrkB receptors, stimulating PI3K-Akt signaling:

• Neuroprotective effects: Prevents dopaminergic neuron death in vitro and in vivo

• Synaptic plasticity: Enhances synaptic function through Akt-mediated mechanisms

• Clinical challenge: Poor brain penetration limits therapeutic utility

Small Molecule Approaches

Akt Activators

Direct Akt activators under development include:

Indirect Activators

Several FDA-approved drugs indirectly activate PI3K-Akt:

• Metformin: Activates LKB1-AMPK, upstreams of Akt pathway

• Exenatide: GLP-1R agonist activates PI3K-Akt through insulin signaling

• Lithium: Inhibits GSK-3β, downstream of Akt

Gene Therapy Approaches

Combination Therapies

Rationale for Combination Approaches

Given the complexity of PD pathogenesis, PI3K-Akt targeted therapies may be combined with:

Patient Selection

Genetic Subtypes

Patients most likely to benefit from PI3K-Akt targeting:

• LRRK2 G2019S carriers: Pathway dysregulation documented

• GBA mutation carriers: PI3K-Akt impairment from glucocerebrosidase loss

• PINK1/PARKIN mutations: Akt-mediated survival pathways compensatory

Disease Stage

• Early stage (Hoehn-Yahr 1-2): Maximum benefit from neuroprotective therapy

• Mid stage (Hoehn-Yahr 2.5-3): May slow progression

• Late stage: Limited benefit due to neuron loss

Biomarker Selection

Adverse Effects and Safety

Growth Factor Therapy Risks

• Intracranial delivery: Risk of infection, hemorrhage

• Immunogenicity: Antibody formation against delivered proteins

• Off-target effects: Non-specific neurotrophic effects

Small Molecule Considerations

• Metabolic effects: Hyperglycemia with some Akt activators

• Cardiovascular: Potential effects on cardiac function

• Cancer risk: Long-term Akt activation concerns

Future Directions

Emerging Targets

• PI3K isoform-specific inhibitors/activators: Targeting neuronal PI3K-C2α

• Akt isoform-selective modulators: Akt1 vs Akt2 specificity

• PTEN inhibitors: Restoring PIP3 production

Clinical Trial Design

• Neuroprotective trials: Require long duration, biomarker enrichment

• Combination designs: Multi-arm trials with multiple mechanisms

• Personalized medicine: Genetic stratification for optimal response

Cross-Linked Pages

• [proteins/akt] - Akt/PKB

• [proteins/gsk3b] - GSK-3β

• [proteins/mtor] - mTOR

• [proteins/gdnf] - GDNF

• [proteins/bdnf] - BDNF

• [genes/parkin] - PARKIN

• [genes/pink1] - PINK1

• [genes/lrrk2] - LRRK2

• [genes/gba] - GBA

• [mechanisms/mitochondrial-dysfunction] - Mitochondrial Dysfunction

• [mechanisms/autophagy-lysosome-pathway] - Autophagy

• [mechanisms/insulin-signaling-neurodegeneration] - Insulin Signaling

• [diseases/parkinsons-disease] - Parkinson’s Disease

Summary

The PI3K-Akt pathway provides critical survival signals for dopaminergic neurons, and its dysfunction contributes to multiple aspects of PD pathogenesis. Therapeutic strategies targeting this pathway, including growth factor delivery, small molecule activators, and gene therapy approaches, represent promising avenues for disease modification in PD. Clinical translation remains challenging due to delivery issues and pathway complexity, but biomarker-driven patient selection and combination approaches offer promise for future development.